Preclinical development of antibacterial compounds
Drug resistant bacterial infections pose a major threat to public health in the United States. Traditional antibiotics have been developed to target a specific essential process causing cell death or preventing growth. This method is becoming less effective since antibiotic resistance has risen sharply among clinical isolates over the last two decades. This project will explore new methods for identifying novel antibacterial compounds using a high throughput screening approach. We will target protein-protein interactions and inhibit processes that prevent bacteria from becoming virulent. Hit compounds will be subjected to structure-activity analysis to determine which features are important for their activities and to optimize compound efficiency. Subsequently, the lead compounds will be tested for their range of effect on several Gram-negative and Gram-positive pathogens. Using a series of genetic and biochemical approaches we will determine the physiological effect that each lead compound has on bacterial growth or virulence during infection.
Identification of Small Molecule Inhibitors of the Type II Secretion System in Acinetobacter baumannii
Presented at ASM Microbe Boston 2016